Prot #INCB 18424-306: A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo

Project: Research project

Project Details

StatusFinished
Effective start/end date8/5/19 → 6/1/23

Funding

  • Premier Research International, LLC ((OE) Prot #INCB 18424-306 // (OE) Prot #INCB 18424-306)
  • Incyte Corporation ((OE) Prot #INCB 18424-306 // (OE) Prot #INCB 18424-306)